|
|
 |
 |
| |
 Printable version |
Has imiquimod 5% cream a role in the management of recurrent basal cell carcinoma? |
European Journal of Dermatology. Volume 19, Number 5, 481-3, September-October 2009, Therapy
|
 Free Article
|
Author(s) : Ricardo Ruiz-Villaverde, Daniel Sánchez-Cano, Pilar Burkhardt-Pérez, Ramon Naranjo Sintes |
Summary : Basal cell carcinoma (BCC) is a cutaneous malignancy with a tendency to spread locally and with several clinical and histological subsets. We studied 34 patients with a clinical diagnosis of recurrent BCC on different anatomical locations, to whom imiquimod 5% cream was administered on a low-frequency regime (3 times a week for 6 weeks), with a minimum of 3 years follow-up after completion of treatment. Clinical clearance rate at 1, 2 and 3 years were 94, 76 and 70%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of recurrent BCC in patients with associated co-morbidities. |
Keywords : basal cell carcinoma, imiquimod |
|
